Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Denmark's Ascendis Forms $80 Million China Rare Disease JV with Vivo Capital

publication date: Nov 9, 2018

Ascendis Pharma of Denmark formed a China JV with Vivo Capital to develop its endocrinology rare disease therapies in Greater China. An investor syndicate, led by Vivo Capital, will own a 50% stake in Visen Pharma, the JV, in return for a $40 million investment. Sofinnova also participated in the funding. Ascendis will transfer China rights to three of its rare disease drugs into Visen and own the remaining 50%. The three Ascendis products -- TransCon hGH, TransCon PTH and TransCon CNP -- are in late-stage clinical trials outside of China.

Stock Symbols: (NSDQ: ASND)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.